...
首页> 外文期刊>Clinical nephrology >The effect of angiotensin receptor blockade ARB on the regression of left ventricular hypertrophy in hemodialysis patients: comparison between patients with D allele and non-D allele ACE gene polymorphism.
【24h】

The effect of angiotensin receptor blockade ARB on the regression of left ventricular hypertrophy in hemodialysis patients: comparison between patients with D allele and non-D allele ACE gene polymorphism.

机译:血管紧张素受体阻滞剂ARB对血液透析患者左室肥厚消退的影响:D等位基因和非D等位基因ACE基因多态性患者的比较。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE: It is revealed that LVH is one of risk factors for the development of cardiac complications in long-term HD patients. Therefore, maneuvers to reduce hypertrophy of cardium are very important for improving life prognosis. Angiotensin II receptor blockade (ARB) could reduce LVH in general populations without renal failure. However, no conclusive data has been available regarding the clinical consequences of ARB administration on the regression of LVH in HD patients. Furthermore, it has not clearly determined if ACE gene polymorphism has a possible influential effect on it. This study is conducted to clarify these issues. SUBJECTS AND METHOD: 32 hypertensive patients on regular HD (male/female: 21/11, mean age: 60.5 years, mean duration of HD: 52.8 months) were studied. Patients were classified into two groups according to the different type of ACE gene polymorphism: cases with D allele (DD/ID; D group: n = 13) and those without (II; non-D group: n = 19). All patients were administered ARB (losartan 50 - 100 mg/day) and echocardiography (UCG) was performed at 6-month-interval regularly until the end of observation (24 months). RESULTS: Before the commencement of ARB, no differences were found between the two groups, neither in mean blood pressure (MBP: D groupon-D group: 120 +/- 13 vs. 115 +/- 14 mmHg) nor in left ventricular mass index (LVMI: Don-D: 172 +/- 41 vs. 165 +/- 41 g/m2). During the 24r-month follow-up, there were significant and similar reductions in MBP in both groups. In respect to LVMI, a significant reduction of LVMI was found in the D group after six months (p < 0.01 vs. basal) with a final reduction rate (FRR) -26 +/- 13%, whereas in the non-D group it was found at 24 months (p < 0.01 vs. basal) with FRR -11 +/- 16% (p < 0.01 vs. D group). There were significant differences between the two groups at all points (p < 0.05 at 6, 18 and 24 months, p < 0.005 at 12 months, respectively). CONCLUSION: It is indicated that ARB could insert a regression effect on LVH predominantly in patients with D allele ACE polymorphism, due partly to factor (s) independent of its anti-hypertensive effect.
机译:目的:揭示LVH是长期HD患者发生心脏并发症的危险因素之一。因此,减少心肌肥大的措施对于改善生命预后非常重要。血管紧张素II受体阻滞剂(ARB)可以降低没有肾功能衰竭的普通人群的LVH。但是,尚无关于ARB给药对HD患者LVH消退的临床后果的确凿数据。此外,尚不清楚ACE基因多态性是否可能对其产生影响。进行这项研究是为了澄清这些问题。研究对象和方法:研究了32例常规HD的高血压患者(男性/女性:21/11,平均年龄:60.5岁,平均HD持续时间:52.8个月)。根据ACE基因多态性的不同类型将患者分为两组:D等位基因(DD / ID; D组:n = 13)和无等位基因(II;非D组:n = 19)。所有患者均接受ARB(氯沙坦50-100 mg /天)治疗,并定期间隔6个月进行超声心动图检查(UCG),直至观察结束(24个月)。结果:ARB开始前,两组之间的平均血压(MBP:D组/非D组:120 +/- 13 vs. 115 +/- 14 mmHg)和左侧均无差异心室质量指数(LVMI:D /非D:172 +/- 41对165 +/- 41 g / m2)。在接下来的24个月的随访中,两组的MBP均显着降低且相似。对于LVMI,D组六个月后发现LVMI显着降低(相对于基础,p <0.01),最终降低率(FRR)为-26 +/- 13%,而非D组发现在24个月时(相对于基础,p <0.01),FRR -11 +/- 16%(相对于D组,p <0.01)。两组在所有时间点都有显着差异(分别在6、18和24个月时p <0.05,在12个月时p <0.005)。结论:表明ARB可在D等位基因ACE多态性患者中对LVH起主要的消退作用,部分原因是其抗高血压作用不受其影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号